Actively Recruiting
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Led by University of Pennsylvania · Updated on 2025-10-09
63
Participants Needed
14
Research Sites
167 weeks
Total Duration
On this page
Sponsors
U
University of Pennsylvania
Lead Sponsor
J
Janssen Scientific Affairs, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
CONDITIONS
Official Title
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of psoriatic arthritis meeting CASPAR criteria
- Active psoriatic arthritis with at least one swollen joint
- Clinical Disease Activity index for Psoriatic Arthritis (cDAPSA) score of 10 or higher; for patients without psoriasis, cDAPSA must be above 14
- Currently using or previously used one TNFi and planning to switch due to inadequate response
- Stable dose of up to two oral small molecule or conventional synthetic DMARDs for at least 4 weeks prior to study start
- Stable dose of NSAIDs, glucocorticoids under 10 mg daily, or topical psoriasis medications for at least 4 weeks prior to screening
- Age between 18 and 80 years
You will not qualify if you...
- Prior use of golimumab or any non-TNFi biologic (IL12/23 inhibitors, JAK inhibitors, IL17 inhibitors, or IL23 inhibitors)
- History of adverse events preventing use of TNFi, including drug-induced lupus, allergic reactions, serious infections, heart failure symptoms, or demyelination
- Use of moderate to high doses of glucocorticoids over 10 mg daily
- Already meeting low disease activity criteria at baseline (cDAPSA 14 or less with low psoriasis activity)
- Currently pregnant or actively trying to conceive
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Family Arthritis Center
Loxahatchee Groves, Florida, United States, 33470
Actively Recruiting
2
Healing Rheumatology
Plant City, Florida, United States, 33563
Actively Recruiting
3
Southwest Florida Rheumatology
Riverview, Florida, United States, 33569
Actively Recruiting
4
Parris and Associates
Lilburn, Georgia, United States, 30047
Actively Recruiting
5
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States, 01655
Actively Recruiting
6
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
7
New York University
New York, New York, United States, 10016
Actively Recruiting
8
Cincy Arthritis
Blue Ash, Ohio, United States, 45242
Actively Recruiting
9
Southern Ohio Rheumatology
Wheelersburg, Ohio, United States, 45694
Actively Recruiting
10
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
11
Cumberland Rheumatology
Crossville, Tennessee, United States, 38555
Actively Recruiting
12
Heritage Rheumatology and Arthritis Care
Colleyville, Texas, United States, 76034
Actively Recruiting
13
Texas Arthritis Center
El Paso, Texas, United States, 79902
Actively Recruiting
14
University of Utah
Salt Lake City, Utah, United States, 84132
Actively Recruiting
Research Team
S
Sarah Gillespie
CONTACT
S
Study Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here